Imatinib and nilotinib reverse multidrug resistance in cancer cells by inhibiting the efflux activity of the MRP7 (ABCC10)

PLoS ONE

Volumn 4, Issue 10, 2009, Pages

  Shen, Tong ^a   Kuang, Ye Hong ^a,b   Ashby Jr , Charles R ^a   Lei, Yu ^a   Chen, Angel ^a   Zhou, Ying ^a   Chen, Xiang ^b   Tiwari, Amit K ^a   Hopper Borge, Elizabeth ^c   Ouyang, Jiangyong ^a,d   Chen, Zhe Sheng ^a  

^a ST JOHN'S UNIVERSITY   (United States)

^b CENTRAL SOUTH UNIVERSITY   (China)

^c FOX CHASE CANCER CENTER   (United States)

^d NEW YORK UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

3 (4,5 DIMETHYL 2 THIAZOLYL) 2,5 DIPHENYLTETRAZOLIUM BROMIDE; DASATINIB; DOXORUBICIN; IMATINIB; MULTIDRUG RESISTANCE PROTEIN; MULTIDRUG RESISTANCE PROTEIN 7; NILOTINIB; PACLITAXEL; SPRYCELL; UNCLASSIFIED DRUG; VINCRISTINE; 4 METHYL N (3 (4 METHYLIMIDAZOL 1 YL) 5 (TRIFLUOROMETHYL)PHENYL) 3 ((4 PYRIDIN 3 YLPYRIMIDIN 2 YL)AMINO)BENZAMIDE; 4-METHYL-N-(3-(4-METHYLIMIDAZOL-1-YL)-5-(TRIFLUOROMETHYL)PHENYL)-3-((4-PYRIDIN-3-YLPYRIMIDIN-2-YL)AMINO)BENZAMIDE; ABCC10 PROTEIN, HUMAN; ANTINEOPLASTIC AGENT; PIPERAZINE DERIVATIVE; PYRIMIDINE DERIVATIVE; TETRAZOLIUM; THIAZOLE DERIVATIVE; THIAZOLYL BLUE;

ARTICLE; CANCER CELL; CELL STRAIN HEK293; CONTROLLED STUDY; DRUG SENSITIVITY; DRUG STRUCTURE; GENETIC TRANSFECTION; HUMAN; HUMAN CELL; IC 50; MULTIDRUG RESISTANCE; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN TRANSPORT; REVERSAL REACTION; CELL LINE; CHEMICAL MODEL; DOSE RESPONSE; DRUG RESISTANCE; GENE EXPRESSION REGULATION; GENETICS; METABOLISM; NEOPLASM;

ANTINEOPLASTIC AGENTS; CELL LINE; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG RESISTANCE, MULTIPLE; DRUG RESISTANCE, NEOPLASM; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; MODELS, CHEMICAL; MULTIDRUG RESISTANCE-ASSOCIATED PROTEINS; NEOPLASMS; PACLITAXEL; PIPERAZINES; PYRIMIDINES; TETRAZOLIUM SALTS; THIAZOLES;

EID: 70449564331     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0007520     Document Type: Article

References (26)

1. Jemal A, Siegel R, Ward E, Hao Y, Xu J, et al. (2008) Cancer statistics. CA Cancer J Clin 58: 71-96.
2. Wu CP, Calcagno AM, Ambudkar SV (2008) Reversal of ABC drug transporter-mediated multidrug resistance in cancer cells: Evaluation of current strategies. Curr Mol Pharmacol 1(2): 93-105.
3. Bradbury PA, Middleton MR (2004) DNA repair pathways in drug resistance in melanoma. Anticancer Drugs 15(5): 421-6.
4. Deeley RG, Westlake C, Cole SPC (2006) Transmembrane transport of endoand xenobiotics by mammalian ATP-binding cassette multidrug resistance proteins. Physiol Rev 86: 849-99.
5. Borges-Walmsley MI, McKeegan KS, Walmsley AR (2003) Structure and function of efflux pumps that confer resistance to drugs. Biochem J 376(Pt 2): 313-38.
6. Naramoto H, Uematsu T, Uchihashi T, Doto R, Matsuura T, et al. (2007) Multidrug resistance-associated protein 7 expression is involved in cross-resistance to docetaxel in salivary gland adenocarcinoma cell lines. Int J Oncol 30(2): 393-401.
7. Hopper-Borge E, Chen ZS, Shchaveleva I, Belinsky MG, Kruh GD (2004) Analysis of the drug resistance profile of multidrug resistance protein 7 (ABCC10): resistance to docetaxel. Cancer Res 64: 4927-30.
8. Hopper-Borge E, Xu X, Shen T, Shi Z, Chen ZS, et al. (2009) Human multidrug resistance protein 7 (ABCC10) is a resistance factor for nucleoside analogues and epithilone B. Cancer Res 69(1): 178-84.
9. Zhou Y, Hopper-Borge E, Shen T, Huang XC, Shi Z, et al. (2009) Cepharanthine is a potent reversal agent for MRP7 (ABCC10)-mediated multidrug resistance. Biochem Pharmacol 77: 993-1001.
10. Shi Z, Peng XX, Kim IW, Shukla S, Si QS, et al. (2007) Erlotinib (Tarceva, OSI-774) antagonizes ATP-binding cassette subfamily B member 1 and ATP-binding cassette subfamily G member 2-mediated drug resistance. Cancer Res 67(22): 11012-20.
11. Dai C, Tiwari AK, Wu CP, Su XD, Wang SR, et al. (2008) Lapatinib (Tykerb, GW572016) reverses multidrug resistance in cancer cells by inhibiting the activity of ATP-binding cassette subfamily B member 1 and G member 2. Cancer Res 68(19): 7905-14.
12. Tiwari AK, Sodani K, Wang SR, Kuang YH, Ashby CR Jr, et al. (2009) Nilotinib (AMN107, Tasigna) reverses multidrug resistance by inhibiting the activity of the ABCB1/Pgp and ABCG2/BCRP/MXP transporters. Biochem Pharmacol 78(2): 153-61.
13. Mendelsohn J, Baselga J (2003) Status of epidermal growth factor receptor antagonists in the biology and treatment of cancer. J Clin Oncol 21(14): 2787-99.
14. Hirota S, Isozaki K, Moriama Y, Hashimoto K, Nishida T, et al. (1998) Gain-of-function mutations of c-KIT in human gastrointestinal stromal tumors. Science 279: 577-80.
15. Shah NP, Nicoll JM, Nagar B, Gorre ME, Paquette RL, et al. (2002) Multiple BCR-ABL kinase domain mutations confer polyclonal resistance to the tyrosine kinase inhibitor imatinib (STI571) in chronic phase and blast crisis chronic myeloid leukemia. Cancer Cell 2: 117-25.
16. + cells and is inhibited by imatinib mesylate. Blood 108(4): 1370-3.
17. Schittenhelm MM, Shiraga S, Schroeder A, Corbin AS, Griffith D, et al. (2006) Dasatinib (BMS-354825), a dual SRC/ABL kinase inhibitor, inhibits the kinase activity of wild-type, juxtamembrane, and activation loop mutant KIT isoforms associated with human malignancies. Cancer Res 66(1): 473-81.
18. Hiwase DK, Saunders V, Hewett D, Frede A, Zrim S, et al. (2008) Dasatinib cellular uptake and efflux in chronic myeloid leukemia cells: therapeutic implications. Clin Cancer Res 14(12): 3881-8.
19. Gora-Tybor J, Robak T (2008) Targeted drugs in chronic myeloid leukemia. Curr Med Chem 15(29): 3036-51.
20. Akiyama S, Fojo A, Hanover JA, Pastan I, Gottesman MM (1985) Isolation and genetic characterization of human KB cell lines resistant to multiple drugs. Somat Cell Mol Genet 11(2): 117-26.
21. Sumizawa T, Chen ZS, Chuman Y, Seto K, Furukawa T, et al. (1997) Reversal of multidrug resistance-associated protein-mediated drug resistance by the pyridine analog PAK-104P. Mol Pharmacol 51(3): 399-405.
22. Bradford MM (1976) A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal Biochem 72: 248-54.
23. Dean M, Fojo T, Bates S (2005) Tumor stem cells and drug resistance. Nat Rev Cancer 5(4): 275-84.
24. Couture L, Nash JA, Turgeon J (2006) The ATP-bind cassette transporters and their implications in drug disposition: a special look at the heart. Pharmacol Rev 58(2): 244-58.
25. Kantarjian H, Giles F, Wunderle L, Bhalla K, O'Brien S, et al. (2006) Nilotinib in imatinib-resistant CML and Philadelphia chromosome-positive ALL. New Eng J Med 354(24): 2542-51.
26. Tanaka C, Yin OQ, Sethuraman V, Smith T, Wang XF, et al. Clinical pharmacokinetics of the BCR-ABL tyrosine kinase inhibitor nilotinib. Clin Pharmacol Ther, In press.